Zacks Investment Research issued a report on Cerulean Pharma Inc (NASDAQ:CERU), raising its target price to $1.00 today
- Updated: October 5, 2016
Boasting a price of $1.00, Cerulean Pharma Inc (NASDAQ:CERU) traded 0.00% even on the day. With the last close down -55.76% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Cerulean Pharma Inc has recorded a 50-day average of $1.08 and a two hundred day average of $2.26. Volume of trade was down over the average, with 368,889 shares of CERU changing hands under the typical 621,905
Cerulean Pharma Inc (NASDAQ:CERU) had its price target upped to $1.00 by Zacks Investment Research in an issued report announced Wednesday October 05, 2016. The new stock price target indicates steady performance relative to the company's last stock close price.
Previously on 8/30/2016, Barclays reported about Cerulean Pharma Inc (NASDAQ:CERU) lowered the target price from $5.00 to $2.00. At the time, this indicated a possible upside of 0.94%.
With a total market value of $0, Cerulean Pharma Inc has with a one year low of $0.92 and a one year high of $4.33 .
A total of 7 brokers have issued a research note on the stock. Four analysts rating the company a strong buy, three equity analysts rating the stock a buy, 0 analysts rating the company a hold, 0 brokers rating the stock a underperform, and finally zero equity analysts rating the stock a sell with a consensus target price of $9.43.
About Cerulean Pharma Inc (NASDAQ:CERU)
Cerulean Pharma Inc. is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads. Its NDC platform is designed to create NDCs that accumulate high concentrations of active drug in tumor cells, without exposure to healthy tissue. Its platform is applicable to a range of payloads. It has created NDCs with a range of small molecule payloads, including Jevtana (cabazitaxel), gemcitabine, methotrexate and Xeljanz (tofacitinib). The Company's product pipeline consists of CRLX101 and CRLX301. Its CRLX101 is a tumor targeted NDC. Its CRLX301 has docetaxel as its anti-cancer payload. CRLX101 has a camptothecin payload, which is a topoisomerase 1 (topo 1) inhibitor. CRLX301 is designed to concentrate docetaxel in tumor cells and spare healthy tissue.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.